6/5/2025 03:19pm
The deep research logic is organized as follows:
Okay, let's tackle this question about BioVie's (BIVI) stock forecast. The user is asking for the latest forecast, so I need to gather all the relevant data from the provided references.
First, I'll check the references for any recent analyst ratings or price targets. Looking at the references, there are a few key ones. Reference 3 from TipRanks mentions an average price target of $6.00 with a 460.75% upside from $1.07. That's a significant jump. But wait, the current price mentioned there is $1.07, which might be outdated since the current time is 2025-06-05. Let me check other sources for more recent data.
Reference 4 from StockNews.com has data up to 2023-11-30, showing an average target of $50, but that seems way too high compared to other sources. Maybe that's an older figure. Reference 5 from GuruFocus mentions an average target of $5.50 with a 354.55% upside from $1.21. That's more recent, from 2025-05-05.
Reference 6 from MarketBeat has a 2024 forecast with an average target of $6.33, a 139.90% upside from $2.64. But the current price might have changed. Reference 8 from Public.com states a consensus rating of Strong Buy with a $3.00 target, but that seems conflicting. Wait, maybe that's an older target.
Looking at the latest references, Reference 19 from Yahoo Finance shows an average target of $6.00 with a current price of $1.095. That's as of 2025-06-05. Reference 20 from MarketWatch also mentions an average target of $6.00. So the most recent data points to a $6.00 average target.
The user is interested in clinical trials and forecasts, so I should highlight BioVie's pipeline. References 5, 11, and 12 mention advancements in Bezisterim for Alzheimer's, Parkinson's, and long COVID, as well as BIV201 for liver cirrhosis with FDA Fast Track. These developments are crucial for the stock's upside potential.
Also, the user follows tech and biotech, so emphasizing the innovative aspect of BioVie's treatments would resonate. The price targets vary, but the most recent consensus seems to be around $6.00. The upside from the current price of $1.095 is about 448%, which is substantial.
I need to structure the answer with a clear conclusion first, then break down the analysis into sections like Price Targets, Clinical Pipeline, Analyst Sentiment, and Risks. Using tables to present the data will make it clearer. Also, since the user prefers detailed analysis, I'll include the latest data points and reconcile any discrepancies in the price targets from different sources.
Make sure to cite the references properly using the [^Number] format and include the visualization for the "BIVI Analyst Average Price Target" query as per the requirements. Since the query results for that were 0, maybe the visualization isn't needed, but I should check the format requirements again. Oh, the visualization is only needed if the query in the references has results. Since the query for BIVI Analyst Average Price Target (Number 1) has 0 results, no visualization is needed there.
Also, the user's profile mentions interest in forecasts and clinical trials, so I'll make sure to highlight those sections. The conclusion should summarize the key points, emphasizing the high upside potential based on the pipeline and recent analyst activity.
I need to ensure the language is professional but engaging, using emojis where appropriate. The answer should be comprehensive, starting with the conclusion, followed by detailed analysis with tables and key points. Let me organize the data from the references into the sections mentioned and make sure all relevant points are covered without fabricating any information.
Conclusion 🌟
BioVie Inc. (BIVI) presents a compelling opportunity for biotech investors with a 448% upside potential based on the latest analyst consensus. The stock is riding a wave of clinical progress in neurodegenerative diseases and liver therapies, supported by a $6.00 average price target and a Strong Buy rating from Wall Street. However, caution is warranted due to high volatility and early-stage clinical risks.
📊 Key Forecast Analysis
1. Price Targets & Upside
| Metric | Value (as of 2025-06-05) |
|---|---|
| Average Price Target | $6.00 12 |
| Current Price | $1.095 2 |
| Upside Potential | 448% 12 |
| High Target | $30.00 14 |
| Low Target | $3.00 5 |
Analysis: The consensus reflects optimism around BioVie’s pipeline, with Bezisterim (for Alzheimer’s, Parkinson’s, and long COVID) and BIV201 (liver cirrhosis) leading the charge. However, the wide target range ($3.00–$30.00) highlights uncertainty in execution risks.
2. Clinical Pipeline Progress
| Drug Candidate | Indication | Stage/Status 67 |
|---|---|---|
| Bezisterim | Alzheimer’s, Parkinson’s, Long COVID | Phase 2/3 trials ongoing |
| BIV201 | Liver Cirrhosis | Phase 3 (FDA Fast Track) |
Key Milestones:
- Bezisterim: Expected topline data for long COVID (2026) and Parkinson’s (2025).
- BIV201: Potential FDA approval by 2026 for ascites treatment.
Rationale: These therapies address high-need areas with limited treatments, offering orphan drug potential and fast-track benefits.
3. Analyst Sentiment
| Metric | Value (as of 2025-06-05) |
|---|---|
| Consensus Rating | Strong Buy 82 |
| Number of Analysts | 1–3 12 |
| Upside vs. Peers | >1442% 4 |
Analysis: BioVie’s Strong Buy rating aligns with its high-risk, high-reward profile. Analysts emphasize the transformative potential of its pipeline but caution against execution risks (e.g., clinical trial delays).
4. Risks & Cautions
- High Volatility: Biotech stocks like BIVI are prone to sharp swings based on clinical data.
- Funding Needs: BioVie’s cash reserves may require additional financing for late-stage trials.
- Regulatory Hurdles: FDA approval timelines for BIV201 and Bezisterim remain uncertain.
🎯 Final Take
BioVie’s $6.00 price target and 448% upside make it a high-conviction pick for biotech bulls. However, the stock’s success hinges on clinical trial outcomes and FDA approvals. For a medium-to-long-term horizon, BIVI offers breakout potential in the neurodegenerative and liver disease spaces.
Bottom Line: Buy if you’re comfortable with high risk and excited about BioVie’s innovative therapies. 🚀
